Back to Search
Start Over
Phase II study: the combination DTIC, BCNU, actinomycin D, and vincristine in disseminated malignant melanoma.
- Source :
-
Medical and pediatric oncology [Med Pediatr Oncol] 1986; Vol. 14 (2), pp. 86-7. - Publication Year :
- 1986
-
Abstract
- Thirty patients with disseminated malignant melanoma received the combination DTIC, BCNU, actinomycin D, and vincristine. The objective response rate was 17 percent concomitant with moderate-to-severe nausea and vomiting in 80 percent of patients. Hematologic toxicity was transient. In the dose and schedule that we used, the four-drug regimen does not offer meaningful benefit for patients with advanced melanoma.
- Subjects :
- Adult
Aged
Antineoplastic Combined Chemotherapy Protocols adverse effects
Carmustine administration & dosage
Dacarbazine administration & dosage
Dactinomycin administration & dosage
Drug Evaluation
Female
Humans
Male
Middle Aged
Vincristine administration & dosage
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Melanoma drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 0098-1532
- Volume :
- 14
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Medical and pediatric oncology
- Publication Type :
- Academic Journal
- Accession number :
- 3713642
- Full Text :
- https://doi.org/10.1002/mpo.2950140206